Diagnostics & Genomics
G

Genomics

Genomics trades as Genomics and is registered in England as Genomics Ltd, formerly Genomics plc. Its US arm, Genomics Inc., is wholly owned by Genomics Ltd. It was founded in 2014 by University of Oxford geneticists, is led by Professor Sir Peter Donnelly, and has offices in Oxford and London and a US base in Durham, North Carolina. It builds integrated risk tools that combine polygenic risk scores with established clinical risk models.

Its clinical product, Health Insights, turns a saliva sample into integrated risk estimates for prevention and screening. In the UK it covers cardiovascular disease, type 2 diabetes, breast cancer and prostate cancer, is UKCA marked and MHRA registered, and is offered through providers including Bupa, Spire Healthcare and Well Life Clinics. In the US, people join with an invitation code from a partner such as MassMutual, which pays for its life insurance policyholders. The test is ordered by the person's own physician or one at SteadyMD, run in a CLIA certified laboratory, and adds atrial fibrillation, high LDL cholesterol, high blood pressure and low bone density. Genomics also sells risk tools to insurers and employers.

In the HEART study in NHS primary care, adding genetics to the QRISK cardiovascular calculator meaningfully changed risk for 24 percent of participants and would have changed clinical management for 13 percent, according to the company. Genomics also sells Mystra, a genetics platform for drug discovery teams.

Genomics holds BSI certification to ISO/IEC 27001 and ISO 13485. No price is published.

AI Health Index verifiedNovember 8, 2026
Compare Genomics with other vendors
Founded
2014
Headquarters
Oxford, United Kingdom
Categories
diagnostics-and-genomics
Indexed Products
Health Insights UK, Health Insights USA, Integrated risk tools (cardiovascular disease, type 2 diabetes, breast and prostate cancer), Mystra
Buyer Segments
Health systems and primary care, Private healthcare providers, Insurers, Employers, Pharma / Life Sciences
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
AA on AI CentralityThe artificial intelligence is the product. Remove the model and there is nothing left to sell.
Vendor Published

The model is the product. What Health Insights sells is a risk estimate: polygenic risk scores, models fitted to large genotyped populations that combine information from millions of places in the genome, integrated with established clinical risk factors to estimate a person's risk of up to seven conditions, from cardiovascular disease and type 2 diabetes to breast or prostate cancer. The saliva kit and genotyping are the input; without the fitted scores there is no result to report. Mystra, sold to drug discovery teams, is likewise an analysis platform built on genetic data.

CC on Autonomy and Oversight ModelAutonomy is claimed and oversight is asserted without a mechanism. Human in the loop appears as a phrase rather than a described control.
Vendor Published

An ordering physician and a clinic consultation surround the score, and the controls around them are not described. In the UK, a clinic registers the patient, receives the report and holds a follow up consultation of about 20 minutes. In the US, the person's own physician or one at SteadyMD orders the test, results are released to the person online with lifestyle and medical actions to discuss with a doctor, and the laboratory report goes to the ordering physician.

Nothing published says when a score is withheld for people outside validated ancestries, or how a revised model changes results already issued.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

The approach is named, without version and update discipline. Genomics combines polygenic risk scores built from millions of variants with clinical models, naming QRISK3 for cardiovascular risk and QDiabetes for type 2 diabetes in the UK. In the US it refines average risk for a person's age, sex and ethnicity, drawn from US population data, and reports risk over the next 10 years or by age 80. A 2023 derivation and validation paper by Genomics is listed on its science page. No model version or update practice is set out.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

The model chain is in house, and the US service names most of its partners. Genomics builds its own polygenic and integrated risk models, with no outside model provider. The Health Insights privacy notice names Clinical Enterprise for genotyping in a CLIA certified laboratory, SteadyMD for ordering physicians, Amazon Web Services for hosting, and Datadog, Auth0, HubSpot and Amplitude on the website, and says each provider is bound by contract to confidentiality and security.

Test kit, customer support and payment providers are not named, and the UK laboratories are described only as ISO 15189 certified.

BB on Clinical and Operational EvidenceNamed deployments with dated outcome figures and enough method to test them, or published research short of independent validation.
Vendor Published

A named NHS study with dated figures, reported by the company. Genomics reports that in the HEART study in NHS primary care, integrating genetics with the QRISK cardiovascular calculator produced clinically significant changes in risk for 24 percent of participants, and that 13 percent would have received different clinical management. It also says its risk scores have been adopted by UK Biobank and Our Future Health, and that Health Insights is in use through Bupa, Spire Healthcare and Well Life Clinics.

The figures describe changes in risk category and intended management rather than events prevented, and the study's publication and method are not set out on the pages describing it. No outcome results for US patients are published.

AA on AI Safety and PHI StewardshipRetention windows, training use and de identification are all stated specifically enough to be contradicted. Safety engineering, meaning guardrails, hallucination mitigation and how a safety event is handled, does not gate this grade: no vendor in this index publishes it, so every note on this axis states that gap rather than leaving it implied.
Vendor Published

Retention, research use and de identification are stated for Health Insights in the United States. Its privacy notice keeps genetic data, risk scores and results for up to 20 years, has the laboratory destroy remaining saliva and DNA 30 days after genotyping, and keeps de identified data indefinitely for research and development aimed at improving Genomics' science and products. De identified data drops name and contact details, keeps genetic data, ethnicity, age, sex, risk scores and survey, support and web data, and is held apart from the data used to produce results. A person can ask that their data stay out of new research, though data already in use cannot be withdrawn.

The UK corporate policy keeps research data indefinitely and online service data up to six years. Safety engineering for the risk scores, meaning how a faulty score would be detected and handled, is not published.

Regulatory and Compliance
BB on HIPAA and BAA PostureBusiness associate status is stated and supported by a substantive privacy document, with the agreement or its scope not fully published. For a vendor outside the United States, an equivalent regime documented to this depth grades here. A vendor whose product does not process protected health information grades here too when it says so plainly and explains the scope, with a service privacy document behind it: stating a position a buyer can rely on is the posture this axis grades, and the band above is closed to it because there is no agreement to publish.
Vendor Published

The US product states plainly that HIPAA does not apply and explains why, with a service privacy notice behind it. The Health Insights privacy notice, updated 30 May 2025, says Genomics is not a covered entity and the service involves no HIPAA standard transactions, and that its privacy and security processes are designed to meet HIPAA requirements as far as practical. It names Genomics Ltd and Genomics Inc. as the companies using the data, places US users under UK GDPR as well as US genetic testing and state consumer health data laws, and sets out rights and retention.

In the UK, Genomics Ltd's corporate privacy policy names the company as data controller under UK data protection law.

BB on Security Certifications and Trust CenterA recognized certification is named in the vendor own material without the artifact, or with a scope or renewal question the buyer has to raise. A recognized certification here is an audit of how the vendor operates security, such as SOC 2, HITRUST or ISO/IEC 27001. A certification has a scope and a clock, and both are part of this grade. A certification the vendor attaches to its data center, hosting facility or cloud provider, rather than presenting as its own, is the host's and does not count here.
Vendor Published

A recognized certification is named without the artifact. Genomics displays BSI certification to ISO/IEC 27001 for information security management, alongside ISO 13485 for medical device quality. Its FAQ says the ISO 27001 certification has covered its scientific data processing infrastructure and systems since 2016. The certificate itself is not published, so its scope for Health Insights USA's systems cannot be checked.

BB on FDA and Regulatory StatusThe pathway is stated and in progress, or a clearance is named without the vintage and scope a buyer needs to match it to the product on offer. A product outside device regulation also sits here when the vendor publishes what it is for and in what setting and the product on offer matches, or names another regime it works under, such as a registration outside the United States. A general clause saying the service is not medical advice does not reach this band.
Vendor Published

A non US regime is named, and the US test runs as a laboratory service. Genomics says Health Insights UK is a UKCA marked device registered with the MHRA. That is a stated regulatory position for the UK product.

In the US, the test is ordered by a physician and run in CLIA certified laboratories, with genotyping by Clinical Enterprise in Massachusetts. No FDA status or laboratory developed test position is named.

BB on AI Governance and Bias DisclosureA governance framework with named process behind it, such as certification to an artificial intelligence management standard, or material written for a customer own review committee to evaluate the product with. A framework covering the vendor whole portfolio counts when its scope reaches this product; what it cannot supply is the product specific evaluation the band above asks for. Published results within the one group where the performance of this product is most at risk also sit here: evaluation on the question this axis asks, short of the comparison across groups the band above requires. A medical device clearance or certification, and the quality system behind it, does not reach this band on its own; it is graded under regulatory status. A regulator reviewed plan governing how the model may change does reach it.
Vendor Published

Results within the groups most at risk are published for the cardiovascular tool. A paper by Genomics and Stanford authors in the American Journal of Cardiology in 2021, listed on the Health Insights science page, reports that the integrated cardiovascular tool improved on the pooled cohort equations in people of White, Black and South Asian ethnicities. Intervals were wider and included no improvement for smaller groups such as Hispanic participants, and results by genetically inferred ancestry were comparable. Genomics holds ISO 13485 for medical device quality management, which governs how the product is built and changed.

Results by ancestry are not set out for the other conditions, and no evaluation by sex or age is published.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

Nothing published stands behind a score once it is issued. In the UK, results come back through the clinic for a follow up consultation. In the US, results are released to the person online and a laboratory report goes to the ordering physician, which lets an implausible result be questioned. The Health Insights privacy notice gives a right to ask for inaccurate data to be corrected, which covers the data rather than the score itself.

No error rate at the thresholds that change care, warranty or remediation commitment is published.

Integration and Deployment
DD on EHR and Interoperability DepthNo integration evidence. A connector described as available on request grades here until one exists.
Vendor Published

No integration evidence is published. UK clinics register patients on the Genomics provider portal and receive the report by secure transfer, and the HEART study ran in NHS primary care, but no record system, standard, marketplace listing or integrated site is described on Genomics' pages for either market.

BB on Deployment Model and Data ResidencyOptions and residency are stated with isolation or the processing path left open.
Vendor Published

Residency is committed for the US product, and the processing path is partly set out. The Health Insights privacy notice says genetic data, risk scores and results are hosted by Amazon Web Services in an isolated US region and do not leave the United States, though Genomics staff can reach them from the UK or the US. Genomics' corporate policy says its genomic data analysis services, including Mystra, run on servers primarily in the UK, names Mythic Beasts as website hosting, and allows transfers under standard contractual clauses or adequacy decisions.

Health Insights is offered only as a hosted service, and isolation between customers is not described.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

No price is published and how the product is sold can be established. Health Insights reaches UK patients through private providers such as Bupa, Spire Healthcare and Well Life Clinics. In the US, people join with an invitation code from a partner, and MassMutual meets the cost for its policyholders. Genomics sells risk tools to insurers and employers and Mystra to drug discovery teams. No test price, per member fee or platform license is set out on Genomics' pages.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

Coverage is named with validation behind part of it. Health Insights covers cardiovascular disease, type 2 diabetes, breast cancer and prostate cancer for adults in the UK, and adds atrial fibrillation, high LDL cholesterol, high blood pressure and low bone density in the US, all for prevention and screening. The cardiovascular tool has NHS primary care study results and a peer reviewed validation across ethnicities behind it. Published evidence for the other conditions is not set out on Genomics' pages.

Alternatives

Alternatives to Genomics

Other products that do the same kind of work as Genomics, and what each one does.

All Genomics alternatives, with prices →

MyOme is a genomics company in Menlo Park, California, with a CLIA certified and CAP accredited laboratory, that sells whole genome screening built around integrated risk scores.

Allelica, based in San Francisco, builds polygenic risk scores and sells them several ways.

Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing of cell free DNA from a blood draw, with machine learning classifiers that detect a cancer signal and predict its origin, across more than 50 cancer types.

Veracyte sells genomic tests that pair a laboratory expression assay with a learned classifier, used by urologists, oncologists and endocrinologists to decide how intensively to treat a cancer or whether a thyroid nodule needs surgery.

Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.

Cloud genomics analysis company (NASDAQ: SOPH) based in Rolle, Switzerland and Boston.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published
Health Insights sold through UK private providers and by partner invitation in the US; risk tools sold to insurers and employers; Mystra sold to drug discovery teams. No unit of charge published. Not applicable as stated. The Health Insights privacy notice says Genomics is not a HIPAA covered entity and HIPAA does not apply, with processes designed to meet HIPAA as far as practical. Not published. Vendor Published

Genomics names its channels (Bupa, Spire Healthcare and Well Life Clinics in the UK, invitation through partners such as MassMutual in the US, insurers, employers, drug discovery teams) without a test price, per member fee or platform license.

Genomics pricing in full →